Baicalein Inhibits the SMYD2/RPS7 Signaling Pathway to Inhibit the Occurrence and Metastasis of Lung Cancer

Lin Gu; Feng Xu; Xiaoli Zhang; Zhihui Gu

doi:10.1155/2022/3796218

Baicalein Inhibits the SMYD2/RPS7 Signaling Pathway to Inhibit the Occurrence and Metastasis of Lung Cancer

J Oncol. 2022 Apr 8:2022:3796218. doi: 10.1155/2022/3796218. eCollection 2022.

Authors

Lin Gu¹, Feng Xu², Xiaoli Zhang¹, Zhihui Gu³

Affiliations

¹ Pharmacy Department, Qingpu Traditional Chinese Medicine Hospital, Shanghai 201700, China.
² Pharmacy Department, Shanghai Sixth people's Hospital South Affiliated to Shanghai Jiaotong University, Shanghai 200233, China.
³ Hospital Director's Office, Qingpu Traditional Chinese Medicine Hospital, Shanghai 201700, China.

Abstract

Objective: This study investigated the potential effects of Baicalein on proliferation, migration, and invasion of human lung cancer A549 and NCI-H1299 cells and its possible mechanisms.

Methods: The effects of Baicalein on proliferation and invasion of A549 and NCI-H1299 cells were detected by MTT assay, clonogenesis assay, and Transwell assay. A subcutaneous transplanted tumor model was used to evaluate the effects of SMYD2 and Baicalein on the proliferation of lung cancer. Baicalein inhibited in SMYD2/RPS7 signaling pathway in tumor cells was also detected by qRT-PCR.

Results: Baicalein significantly inhibited the growth of lung cancer cells. In addition, Baicalein significantly reduced the rate of A549 and NCI-H1299 cell invasion and clone formation in a dose-dependent manner. Animal experiments showed that both SMYD2 and Baicalein treatments could inhibit lung cancer tumor proliferation. Mechanism studies suggest that Baicalein inhibits the SMYD2/RPS7 signaling pathway.

Conclusion: These results indicated that Baicalein could inhibit the proliferation, migration, and invasion of LUNG cancer A549 and NCI-H1299 cells. Baicalein inhibits cell proliferation by downregulating the SMYD2/RPS7 signaling pathway.